Evidence map›Paper›PMID 40628263›Full record

ArticleCell reports. Medicine2025

Activity-attenuated serum albumin-fused interleukin-33 suppresses experimental autoimmune encephalomyelitis.

Erica Budina, Joseph W Reda, Shijie Cao, Elyse A Watkins, Ani Solanki, Mindy Nguyen, Phillip S Ang, J Emiliano Gómez Medellín, Hye-Rin Chun, Colleen R Foley and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Erica BudinaPritzker School of Molecular Engineering, University of Chicago, Chicago, IL, USA; Department of Chemical and Biomolecular Engineering, Tandon School of Engineering, New York University, Brooklyn, NY, USA.
Joseph W RedaPritzker School of Molecular Engineering, University of Chicago, Chicago, IL, USA.
Shijie CaoPritzker School of Molecular Engineering, University of Chicago, Chicago, IL, USA; Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, WA, USA.
Elyse A WatkinsPritzker School of Molecular Engineering, University of Chicago, Chicago, IL, USA.
Ani SolankiAnimal Resource Center, University of Chicago, Chicago, IL, USA.
Mindy NguyenAnimal Resource Center, University of Chicago, Chicago, IL, USA.
Phillip S AngPritzker School of Molecular Engineering, University of Chicago, Chicago, IL, USA.
J Emiliano Gómez MedellínPritzker School of Molecular Engineering, University of Chicago, Chicago, IL, USA.
Hye-Rin ChunPritzker School of Molecular Engineering, University of Chicago, Chicago, IL, USA.
Colleen R FoleyPritzker School of Molecular Engineering, University of Chicago, Chicago, IL, USA.
Brendan T K BergPritzker School of Molecular Engineering, University of Chicago, Chicago, IL, USA.
Ha-Na ShimPritzker School of Molecular Engineering, University of Chicago, Chicago, IL, USA.
Kevin HultgrenPritzker School of Molecular Engineering, University of Chicago, Chicago, IL, USA.
Zahra KhosraviPritzker School of Molecular Engineering, University of Chicago, Chicago, IL, USA.
Arjun DharPritzker School of Molecular Engineering, University of Chicago, Chicago, IL, USA.
Suzana GomesPritzker School of Molecular Engineering, University of Chicago, Chicago, IL, USA.
Andrew C TremainPritzker School of Molecular Engineering, University of Chicago, Chicago, IL, USA.
Ako IshiharaPritzker School of Molecular Engineering, University of Chicago, Chicago, IL, USA; Department of Bioengineering, Imperial College London, London, UK.
Jun IshiharaPritzker School of Molecular Engineering, University of Chicago, Chicago, IL, USA; Department of Bioengineering, Imperial College London, London, UK.
Jeffrey A HubbellPritzker School of Molecular Engineering, University of Chicago, Chicago, IL, USA; Department of Chemical and Biomolecular Engineering, Tandon School of Engineering, New York University, Brooklyn, NY, USA; Departments of Biology and Chemistry, New York University, New York, NY, USA; Department of Biochemistry and Molecular Pharmacology, NYU Langone Health, New York, NY, USA. Electronic address: j.hubbell@nyu.edu.

Funding

Medical Scientist National Research Service AwardT32GM150375 · NIGMS · UNIVERSITY OF CHICAGO · PI Raghavendra G Mirmira · 2023 to 2026
$5.5M
NIGMS NIH HHS T32 GM150375
6 · The paper itself

Abstract

Interleukin-33 (IL-33) is an immunoregulatory cytokine that moderately suppresses experimental autoimmune encephalomyelitis (EAE), a murine model of multiple sclerosis (MS). However, poor pharmacokinetics and toxicity hinder its clinical translation. To address these limitations, we develop an activity-attenuated IL-33 by recombinant fusion to serum albumin (SA). SA-IL-33 exhibits reduced toxicity and prolonged residence in the secondary lymphoid organs (SLOs), sites of T cell priming in autoimmunity, compared to wild-type (WT) IL-33. Prophylactic SA-IL-33 administration prevents EAE with superior efficacy to WT IL-33 and comparable efficacy to fingolimod (FTY720), a Food and Drug Administration (FDA)-approved MS drug. Therapeutic SA-IL-33 treatment also reduces disease severity in both chronic and relapsing-remitting EAE. SA-IL-33 modulates immunity in EAE by suppressing CD45

Indexed as

Encephalomyelitis, Autoimmune, ExperimentalInterleukin-33Recombinant Fusion ProteinsSerum AlbuminAnimalsDisease Models, AnimalFemaleHumansMiceMice, Inbred C57BLMultiple SclerosisSpinal CordTh17 CellsT-Lymphocytes, RegulatoryIl33 protein, mouseInterleukin-33Recombinant Fusion ProteinsSerum Albumincytokine engineeringfingolimodimmunoregulationinterleukin-33lymph nodesmultiple sclerosisneuroinflammationpharmacokineticsserum albumin

Identifiers

PMID40628263
PMCPMC12281425

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.